Ferroquine

Drug Profile

Ferroquine

Alternative Names: SR-97193; SSR-97193

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Aminoquinolines; Antimalarials; Ferrous compounds; Small molecules
  • Mechanism of Action Hemozoin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 27 Aug 2015 No recent reports of development identified - Phase-II for Malaria in Africa and France (PO)
  • 27 Aug 2015 No recent reports of development identified - Phase-II for Malaria (In children) in Africa (PO)
  • 30 Oct 2009 Phase-II clinical trials in African adults and children Malaria in Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top